Cargando…
Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients
Background and Objectives: Immunosuppressed individuals are at particularly increased risk for human papilloma virus-related infections. The primary objective of our study is to determine if there are any adverse effects associated with high-dose cimetidine treatment. A secondary objective is to rep...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024571/ https://www.ncbi.nlm.nih.gov/pubmed/29642499 http://dx.doi.org/10.3390/medsci6020030 |
_version_ | 1783336084531314688 |
---|---|
author | Das, Bibhuti B Anton, Kristin Soares, Nelia Riojas, Susan Mcdermott, Jodi Knox, Leah Daneman, Susan Puente, Bao N |
author_facet | Das, Bibhuti B Anton, Kristin Soares, Nelia Riojas, Susan Mcdermott, Jodi Knox, Leah Daneman, Susan Puente, Bao N |
author_sort | Das, Bibhuti B |
collection | PubMed |
description | Background and Objectives: Immunosuppressed individuals are at particularly increased risk for human papilloma virus-related infections. The primary objective of our study is to determine if there are any adverse effects associated with high-dose cimetidine treatment. A secondary objective is to report our experience with cimetidine in the treatment of cutaneous warts in pediatric heart transplant recipients. Methods and Results: This was a retrospective observational study. A total of 8 pediatric heart transplant recipients diagnosed with multiple recalcitrant warts were the subject of the study. All patients were treated with cimetidine (30–40 mg/kg/day) in two divided doses for 3 to 6 month durations. All patients had complete resolution of their lesions except 1 patient who had no clinical improvement. Of these 8 patients, one had recurrence of warts at one year follow-up, which resolved with restarting cimetidine therapy. One patient who had only 3 months of cimetidine therapy had immediate relapse after cimetidine was stopped. None of them had significant change in their tacrolimus trough, serum creatinine, and alanine transaminase levels. No adverse events were reported except one patient experienced mild gynecomastia. Conclusion: Cimetidine can be a safe and alternative treatment option for multiple warts in pediatric heart transplant recipients. |
format | Online Article Text |
id | pubmed-6024571 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-60245712018-07-05 Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients Das, Bibhuti B Anton, Kristin Soares, Nelia Riojas, Susan Mcdermott, Jodi Knox, Leah Daneman, Susan Puente, Bao N Med Sci (Basel) Article Background and Objectives: Immunosuppressed individuals are at particularly increased risk for human papilloma virus-related infections. The primary objective of our study is to determine if there are any adverse effects associated with high-dose cimetidine treatment. A secondary objective is to report our experience with cimetidine in the treatment of cutaneous warts in pediatric heart transplant recipients. Methods and Results: This was a retrospective observational study. A total of 8 pediatric heart transplant recipients diagnosed with multiple recalcitrant warts were the subject of the study. All patients were treated with cimetidine (30–40 mg/kg/day) in two divided doses for 3 to 6 month durations. All patients had complete resolution of their lesions except 1 patient who had no clinical improvement. Of these 8 patients, one had recurrence of warts at one year follow-up, which resolved with restarting cimetidine therapy. One patient who had only 3 months of cimetidine therapy had immediate relapse after cimetidine was stopped. None of them had significant change in their tacrolimus trough, serum creatinine, and alanine transaminase levels. No adverse events were reported except one patient experienced mild gynecomastia. Conclusion: Cimetidine can be a safe and alternative treatment option for multiple warts in pediatric heart transplant recipients. MDPI 2018-04-08 /pmc/articles/PMC6024571/ /pubmed/29642499 http://dx.doi.org/10.3390/medsci6020030 Text en © 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Das, Bibhuti B Anton, Kristin Soares, Nelia Riojas, Susan Mcdermott, Jodi Knox, Leah Daneman, Susan Puente, Bao N Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients |
title | Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients |
title_full | Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients |
title_fullStr | Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients |
title_full_unstemmed | Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients |
title_short | Cimetidine: A Safe Treatment Option for Cutaneous Warts in Pediatric Heart Transplant Recipients |
title_sort | cimetidine: a safe treatment option for cutaneous warts in pediatric heart transplant recipients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6024571/ https://www.ncbi.nlm.nih.gov/pubmed/29642499 http://dx.doi.org/10.3390/medsci6020030 |
work_keys_str_mv | AT dasbibhutib cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients AT antonkristin cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients AT soaresnelia cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients AT riojassusan cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients AT mcdermottjodi cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients AT knoxleah cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients AT danemansusan cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients AT puentebaon cimetidineasafetreatmentoptionforcutaneouswartsinpediatrichearttransplantrecipients |